Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

ta showed that patient self-adjustment of insulin treatment with Levemir® was as safe and effective when compared to dosing that was adjusted by physicians according to standard-of-care. The patients who self-adjusted their dosage achieved a level of diabetes control that was comparable to that of patients receiving physician-driven adjustments. Minimal weight change was observed in both trial arms.1

The findings on weight gain are consistent with previous studies of Levemir®, the first insulin to show less weight gain versus other basal insulins in 12 of 12 controlled clinical trials*. Weight gain is a common side effect of insulin therapy, which is a concern given that 80 percent of people with type 2 diabetes are overweight or obese.

About the Study (Abstract #197-OR):
The new data presented at ADA were from a six-month analysis of 5,604 Type 2 diabetes patients, in a mainly primary care settings, and predominantly treated with Levemir® once-daily, as an add-on therapy to any other glucose-lowering regimens, or as replacement of a previous basal insulin. Patients were randomized to either the “303 Algorithm” [self adjusting their Levemir® dose every three days based on fasting plasma glucose (FPG)] or “Standard-of-Care” (Levemir® dose was physician-adjusted according to standard-of-care) treatment groups.
The study showed that the average A1c, an indicator of long-term blood glucose control, decreased from 8.5 percent at baseline to 7.9 percent at 26 weeks for the 303 Algorithm group, and from 8.5 percent to 8.0 for Standard-of-Care group (p=0.001). Compared to baseline, FPG values decreased by 34 and 21 mg/dL for 303 Algorithm and Standard-of-Care groups, respectively (p<0.0001).
At 26 weeks, 88 percent of all patients remained on once-daily Levemir® therapy. In a subset of insulin-naïve patients who added Levemir® to their standard-of-care therapy, well ove
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
(Date:9/1/2015)... , Sept. 1, 2015 Sargas ... Management (CCM) and Drug Adherence m Health applications ... automate the process of non face-to-face monitoring of ... this new release of our apps, doctors are ... services along with our ONCHIT certified Physician, Pharmacy ...
(Date:9/1/2015)... Sept. 1, 2015   Ivenix Inc. , ... management system, closed on a $42M round of ... Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity ... the round. This financing will support the company,s ... Leerink Partners LLC acted as the exclusive placement ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... telangiectasia-like disease and Nijmegen breakage syndrome offer ... and cancer vulnerability in people carrying the ... Scientists at St. Jude Children,s Research Hospital ... two related neurological diseases--ataxia telangiectasia-like disease (ATLD) ...
... MannKind Corporation (Nasdaq: MNKD ) ... equivalence of its commercial inhaler to the version of ... deliver AFRESA(TM), MannKind,s ultra rapid acting insulin that recently ... Bioequivalence of Clinical and Commercial Scale Inhalers Study 138 ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
(Date:9/1/2015)... ... 01, 2015 , ... USA Medical Card, a leading distributor ... coincide with back-to-school and the start of “sick season” for many households across ... children are sick an average of 8 to 12 times each school year. ...
(Date:9/1/2015)... ... September 01, 2015 , ... AdvantagePlusCaregivers.com® provides information on defining ... what to look for and expect when searching for resources, as well as ... Canoga Park, CA by CEO, Richard Weatherman and Co-Founder Piroska Zalkadi, AdvantagePlusCaregivers.com® grew ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... communications archiving solution integrated with Alfresco‘s enterprise content management system. PRO Archiver ... save millions of dollars in printing costs by digitizing vast amounts of ...
(Date:9/1/2015)... ... 01, 2015 , ... Elizabeth Callahan, MD, founder and medical director of ... to offer RADIESSE® filler treatment for volume loss in the hands. RADIESSE provides an ... in the hands, delivering smooth, natural-looking results that can last up to one year ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices ... take a look at the topic of arthritis. There are over 100 different types ... interesting arthritis types and statistics in an effort to shed light on this important ...
Breaking Medicine News(10 mins):Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3
... an issue than youngsters, tastes, studies find, , , MONDAY, April ... issue of supply than demand in the poorest parts of ... children in these rural areas are open to eating more ... not readily available and could become even less so if ...
... published in the April issue of the Journal ... large numbers of physician assistants and nurse practitioners ... hired by general surgery residency programs in the last ... these professionals continue to be in demand. Most have ...
... of Fit by Sara and Susan G. Komen for the Cure, ... DIEGO, April 20 Word is spreading about YOGA 4 THE ... have gathered together to stretch, deep breathe and meditate. Along ... $1,000 in donations for breast cancer. Susan G. Komen for the ...
... 20 The 7th annual FedEx/St. ... 16, 2009 at 7:00 p.m. at the InterContinental Miami Hotel ... premier pediatric cancer research centers. This year,s event will honor ... Thalia , for their generous support of children in need ...
... PAUL, Minn., April 20 More than 2,000 letter carriers ... Out Hunger on May 9, 2009 in an effort ... by the recession. Stamp Out Hunger is the ... locally supports Second Harvest Heartland, the Upper Midwest,s largest hunger-relief ...
... Australia and Israel has identified a genetic variation that ... The finding is published in the latest edition of ... Helen Leonard, who heads the Australian Rett Syndrome Study ... the finding was exciting in that it identifies a ...
Cached Medicine News:Health News:Kids and Veggies: Offer Them and They Will Eat 2Health News:Surgical education programs have demand for physician assistants and nurse practitioners 2Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 2Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 3Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 2Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 3Health News:7th Annual FedEx/St. Jude Angels & Stars Gala Announces 2009 Honorees Tommy Mottola & Thalia 4Health News:Letter Carriers to Deliver Hope for Those Impacted by Economy 2Health News:Letter Carriers to Deliver Hope for Those Impacted by Economy 3Health News:New insight into Rett syndrome severity 2
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: